CC
EW icon

Cedar Capital’s Edwards Lifesciences EW Stock Holding History

Cedar Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,232
Closed -$976K – 99
2020
Q3 		$976K Buy
12,232
+3,783
+45% +$295K 0.32% 87
2020
Q2 		$584K Buy
8,449
+673
+9% +$47.8K 0.22% 100
2020
Q1 		$489K Sell
7,776
-225
-3% -$16.2K 0.23% 98
2019
Q4 		$622K Buy
8,001
+1,638
+26% +$128K 0.29% 111
2019
Q3 		$466K Buy
6,363
+1,431
+29% +$101K 0.22% 122
2019
Q2 		$304K Sell
4,932
-276
-5% -$16.7K 0.13% 140
2019
Q1 		$332K Sell
5,208
-309
-6% -$17.6K 0.15% 133
2018
Q4 		$282K Sell
5,517
-1,185
-18% -$60K 0.14% 132
2018
Q3 		$389K Buy
6,702
+2,196
+49% +$107K 0.15% 138
2018
Q2 		$219K Buy
+4,506
New +$210K 0.1% 143

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Cedar Capital's EW Position: Q4 2020 in Review

Cedar Capital sold out of Edwards Lifesciences (EW) in Q4 2020, closing a stake of 12,232 shares — an estimated $976K sold.

Cedar Capital first reported a position in EW in Q2 2018 and held it in 10 quarters. The position peaked at $976K in Q3 2020. 1,158 funds tracked by Wall St. Rank hold EW as of Q4 2020.

  • Cedar Capital reported no remaining Edwards Lifesciences position as of Q4 2020 after selling out during the quarter.
  • Cedar Capital sold 12,232 Edwards Lifesciences shares in Q4 2020, an estimated $976K.
  • Cedar Capital first reported a position in Edwards Lifesciences in Q2 2018 and held it in 10 quarters.
  • Cedar Capital's Edwards Lifesciences position peaked at $976K in Q3 2020.
  • 1,158 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2020.

Based on Cedar Capital's 13F filing for Q4 2020, filed 5 Feb 2021.